venBio Partners LLC

CIK 0001776382 · SAN FRANCISCO, CA · Quarter end: 2026-06-30 · Filed on: 2026-08-14 · Open the SEC source ↗

venBio Partners LLC reported 7 positions worth $519.4M as of June 30, 2026 (13F filed August 14, 2026). Largest holding: PHVS (30.9%).

Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.

$519.4M

2026 Q2

Positions

Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.

100.0%

Est. Net Flow (Q)

—

2026 Q2

Positions Changes Mix History BacktestPRO

7 positions shown

#	Symbol	Company	Type	Value ↓	% Port.	Shares	1Y	YTD
▸ 1	PHVS	PHARVARIS N V	SH	$160.6M	30.92%	4,643,430	—	—
▸ 2	PBLS	PARABILIS MEDICINES INC	SH	$144.1M	27.75%	5,266,697	—	—
▸ 3	ALMS	ALUMIS INC	SH	$127.4M	24.53%	4,528,408	—	—
▸ 4	ACHV	ACHIEVE LIFE SCIENCE INC	SH	$38.6M	7.44%	5,914,720	—	—
▸ 5	ALXO	ALX ONCOLOGY HLDGS INC	SH	$26.7M	5.14%	12,884,638	—	—
▸ 6	HRMY	HARMONY BIOSCIENCES HLDGS IN	SH	$17.2M	3.31%	472,194	—	—
▸ 7	LYEL	LYELL IMMUNOPHARMA INC	SH	$4.7M	0.91%	337,697	—	—

Read the 2026-Q2 quarterly report · 13F Filing Calendar

Frequently Asked Questions

What stocks does venBio Partners LLC hold as of Q2 2026?

venBio Partners LLC reported 7 positions worth $519.4M in its Q2 2026 13F filing. Largest positions: PHVS (30.9%), PBLS (27.8%), ALMS (24.5%), ACHV (7.4%) and ALXO (5.1%).

What did venBio Partners LLC buy in Q2 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did venBio Partners LLC sell in Q2 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.